{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:18:15Z","timestamp":1790731095337,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The incidence of Waldenstr\u00f6m macroglobulinemia (WM) has increased in certain groups over several decades in the United States. It is unclear whether the increasing incidence is associated with mortality trends.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The incidence and incidence-based mortality (IBM) rates were obtained from the Surveillance, Epidemiology, and End Results (SEER) database (1980\u20132016) with SEER<jats:sup>*<\/jats:sup>Stat software. The secular trends stratified by demographic characteristics were analyzed by joinpoint regression.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The incidence of WM showed an initial rapid increase from 1980 to 1993 {annual percentage change (APC), 14.1% [95% confidence interval (CI), 10 to 18.4%]}, whereas it began to stabilize from 1993 to 2016 [APC, 0.5% (95% CI, \u22120.3 to 1.3%)]. The WM IBM trend followed a similar pattern, with a decrease occurring around 1994. The trends in the incidence and mortality significantly differed according to geographic location, race, age, sex, primary site of involvement and subtype, which could help in further investigations into the specific etiology. Moreover, a dramatic increase in the 5-year survival rate from the 1980s to 2010s was observed (47.84 vs. 69.41%).<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Although both the incidence and IBM of WM continued to increase during the study period, a reduction in the rate of increase occurred around 1993. We believe that further advances in healthcare delivery and research can ensure a low mortality rate. Future studies can use the findings of this paper to monitor the results of WM therapy.<\/jats:p>","DOI":"10.3389\/fonc.2020.01712","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T04:51:05Z","timestamp":1599713465000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Trends in Incidence and Mortality of Waldenstr\u00f6m Macroglobulinemia: A Population-Based Study"],"prefix":"10.3389","volume":"10","author":[{"given":"Xuejiao","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenli","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"B1","unstructured":"WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview837\n            SabattiniE\n            BacciF\n            SagramosoC\n            PileriSA\n          21171509Pathologica.1022010"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1002\/cncr.26627","article-title":"Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study","volume":"118","author":"Wang","year":"2012","journal-title":"Cancer."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1182\/blood-2014-05-574871","article-title":"Survival trends in Waldenstrom macroglobulinemia: an analysis of the surveillance, epidemiology and end results database","volume":"123","author":"Castillo","year":"2014","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ajh.22027","article-title":"No significant improvement in the outcome of patients with Waldenstrom's macroglobulinemia treated over the last 25 years","volume":"86","author":"Kastritis","year":"2011","journal-title":"Am J Hematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/ajh.23351","article-title":"Patterns of survival in lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005","volume":"88","author":"Kristinsson","year":"2013","journal-title":"Am J Hematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/bjh.13264","article-title":"Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3109\/10428194.2011.557167","article-title":"Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines","volume":"52","author":"Link","year":"2011","journal-title":"Leuk Lymphoma."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3109\/10428194.2012.656103","article-title":"Waldenstrom macroglobulinemia: a surveillance, epidemiology, and end results database review from 1988 to 2005","volume":"53","author":"Sekhar","year":"2012","journal-title":"Leuk Lymphoma."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood.V85.4.1144.bloodjournal8541144","article-title":"Monoclonal gammopathies and hepatitis C virus infection","volume":"85","author":"Mussini","year":"1995","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/ajh.20724","article-title":"Hepatitis C viral infection is not associated with Waldenstr\u00f6m's macroglobulinemia","volume":"82","author":"Leleu","year":"2007","journal-title":"Am J Hematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/cncr.29334","article-title":"Incidence of secondary malignancies among patients with Waldenstrom macroglobulinemia: an analysis of the SEER database","volume":"121","author":"Castillo","year":"2015","journal-title":"Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.hoc.2018.05.006","article-title":"Familial waldenstr\u00f6m macroglobulinemia: families informing populations","volume":"32","author":"McMaster","year":"2018","journal-title":"Hematol Oncol Clin North Am."},{"key":"B13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/ajh.24753","article-title":"IgM myeloma: a multicenter retrospective study of 134 patients","volume":"92","author":"Castillo","year":"2017","journal-title":"Am J Hematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1182\/blood-2013-05-502211","article-title":"MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood."},{"key":"B17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.hoc.2018.05.008","article-title":"Initial Evaluation of the Patient with Waldenstrom Macroglobulinemia","volume":"32","author":"Castillo","year":"2018","journal-title":"Hematol Oncol Clin North Am."},{"key":"B18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.pathol.2019.11.002","article-title":"A practical guide to laboratory investigations at diagnosis and follow up in Waldenstrom macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group","volume":"52","author":"Maqbool","year":"2020","journal-title":"Pathology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.hoc.2018.05.004","article-title":"Flow cytometry","volume":"32","author":"Gascue","year":"2018","journal-title":"Hematol Oncol Clin North Am."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0122338","DOI":"10.1371\/journal.pone.0122338","article-title":"Immunophenotyping of Waldenstroms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications","volume":"10","author":"Paulus","year":"2015","journal-title":"PLoS ONE."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2009-05-174359","article-title":"How i treat Waldenstrom macroglobulinemia","volume":"114","author":"Treon","year":"2009","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180","volume":"27","author":"Treon","year":"2009","journal-title":"J Clin Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood."},{"key":"B24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1053\/sonc.2003.50069","article-title":"Developing diagnostic criteria in Waldenstrom's macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol."},{"key":"B25","unstructured":"Deaths: final data for 20131119\n            XuJ\n            MurphySL\n            KochanekKD\n            BastianBA\n          26905861Natl Vital Stat Rep.642016"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/1055-9965.EPI-08-1118","article-title":"Sex disparities in cancer incidence by period and age","volume":"18","author":"Cook","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.leukres.2007.02.002","article-title":"The incidence and survival of Waldenstrom's Macroglobulinaemia in South East England","volume":"32","author":"Phekoo","year":"2008","journal-title":"Leuk Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3","article-title":"Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994","volume":"82","author":"Groves","year":"1998","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.critrevonc.2014.07.004","article-title":"Reproductive factors and non-Hodgkin lymphoma: a systematic review","volume":"92","author":"Costas","year":"2014","journal-title":"Crit Rev Oncol Hematol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/10428190701809156","article-title":"Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab","volume":"49","author":"Ngo","year":"2008","journal-title":"Leuk Lymphoma."},{"key":"B31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1600-0609.2010.01541.x","article-title":"Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy","volume":"86","author":"Riihijarvi","year":"2011","journal-title":"Eur J Haematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/humupd\/dmi008","article-title":"Sex hormones and the immune response in humans","volume":"11","author":"Bouman","year":"2005","journal-title":"Hum Reprod Update."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/sj.bjc.6602297","article-title":"The age distribution of cancer and a multi-stage theory of carcinogenesis","volume":"91","author":"Armitage","year":"2004","journal-title":"Br J Cancer."},{"key":"B35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.autrev.2004.03.004","article-title":"Inflamm-aging: autoimmunity, and the immune-risk phenotype","volume":"3","author":"Boren","year":"2004","journal-title":"Autoimmun Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12199-018-0740-1","article-title":"Inflammation and cancer","volume":"23","author":"Murata","year":"2018","journal-title":"Environ Health Prev Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00018-012-0970-0","article-title":"Immune aging and autoimmunity","volume":"69","author":"Goronzy","year":"2012","journal-title":"Cell Mol Life Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1371\/journal.pbio.0050201","article-title":"Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation","volume":"5","author":"Chambers","year":"2007","journal-title":"PLoS Biol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"20012","DOI":"10.1073\/pnas.1116110108","article-title":"Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age","volume":"108","author":"Pang","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B40","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fonc.2020.00230","article-title":"Bone Marrow Senescence and the Microenvironment of Hematological Malignancies","volume":"10","author":"Hellmich","year":"2020","journal-title":"Front Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis","volume":"23","author":"Landgren","year":"2009","journal-title":"Leukemia."}],"updated-by":[{"DOI":"10.3389\/fonc.2021.657016","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.01712\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T20:30:35Z","timestamp":1613853035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.01712\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":41,"alternative-id":["10.3389\/fonc.2020.01712"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01712","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fonc.2021.657016","asserted-by":"object"}]},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"article-number":"1712"}}